

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Manx Healthcare Clear Nose Spray

Xylometazoline Decongestant Nasal Spray 0.1% w/v

NasoClear 0.1% w/v Decongestant Nasal Spray

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Xylometazoline Hydrochloride 0.1% w/v

Excipients with known effect

Benzalkonium chloride

Sodium

For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Nasal spray.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

The symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever) and sinusitis.

4.2 Posology and method of administration

i) Posology

Adults, the elderly and children over 12 years of age

One application in each nostril up to 3 times daily. Do not exceed 3 applications daily into each nostril.

Children under 12 years

Not suitable.

(ii) Method of administration

Application to the nasal passages.

The spray pump guarantees a good distribution of the solution on the surface of the mucosa. The dosing mechanism enables an accurate dosage and prevents an unintended overdose.

Remove the protective cap. Before first use, press the pump 5 times until an even spray is formed. The nasal spray is ready for use now. With repeated administration, the nasal spray will be ready for immediate use. If the spray has not been used for a maximum of 14 days (after first use), press the pump once to activate the nasal spray.

Avoid contact with eyes and mouth.

1. Blow your nose.
2. Hold the bottle upright and place your thumb at the bottom of the bottle and hold the nozzle between 2 fingers.
3. Tilt your head forward slightly and put the nozzle in a nostril.
4. Breathe in slowly and gently through your nose whilst pressing down the pump.
5. Clean and dry the nozzle before placing the protective cap.

The recommended dose should not be exceeded, especially in children and the elderly.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Narrow-angle glaucoma.

Rhinitis sicca or atrophic rhinitis.

Xylometazoline Decongestant Nasal Spray 0.1% w/v is contraindicated in children aged less than 12 years.

Use in people with pheochromocytoma, prostatic hypertrophy or those receiving monoamine oxidase inhibitors (MAOI) treatment or who have received them in the last two weeks.

4.4 Special warnings and precautions for use

Patients are advised not to take decongestants for more than seven consecutive days, prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa.

Xylometazoline Decongestant Nasal Spray 0.1% w/v, like other preparations belonging to the same class of active substances should be used only with caution in patients showing a strong reaction to sympathomimetic agents as evidenced by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure.

Caution is recommended in patients with hypertension, cardiovascular disease, hyperthyroidism or diabetes mellitus.

Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias.

Information concerning excipients

Xylometazoline Decongestant Nasal Spray 0.1% w/v contains benzalkonium chloride. This may cause irritation of the nasal mucosa.

This medicine contains less than 1mmol sodium (23mg) per dose, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

The concomitant use of xylometazoline with monoamine oxidase (MAO) inhibitors or tri- and tetra-cyclic antidepressants, may cause an increase in blood pressure due to the cardiovascular effects of these substances (see Contraindications).

4.6 Fertility, pregnancy and lactation

No foetal toxicity or fertility studies on xylometazoline have been carried out in animals.

Pregnancy

In view of its potential systemic vasoconstrictor effect, it is advisable to take the precaution of not using xylometazoline during pregnancy.

Breastfeeding

No evidence of any adverse effect on the breast-fed infant. However, it is not known if xylometazoline is excreted in breast milk, therefore caution should be exercised and Xylometazoline hydrochloride should be used only on the advice of a doctor whilst breast-feeding.

4.7 Effects on ability to drive and use machines

No effects on the ability to drive or to use machines would be anticipated.

4.8 Undesirable effects

The adverse effects listed below are classified by system organ class and frequency according to the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) or very rare ($< 1/10,000$).

MedDRA SOC	Adverse reaction	Frequency
Immune System Disorders	Hypersensitivity reaction (angioedema, rash, pruritus)	Very rare
Nervous System Disorders	Headache	Common
Eye Disorders	Transient visual impairment	Very rare
Cardiac Disorders	Heart rare irregular Heart rate increased	Very Rare
Respiratory, thoracic and mediastinal disorders	Nasal Dryness	Common

	Nasal Discomfort	
	Epistaxis	Uncommon
Gastrointestinal disorders	Nausea	Common
General disorders and administration site conditions	Application site burning	Common

Other side effects include:

- A burning sensation in the nose and throat

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 **Overdose** **Symptoms and Signs**

Excessive administration of topical xylometazoline hydrochloride or accidental ingestion may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.

Treatment

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for several hours.

5 **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Sympathomimetics, plain

ATC Code: R01AA

Xylometazoline is a sympathomimetic agent with marked alpha-adrenergic activity and is intended for use in the nose. It constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. This enables patients suffering from colds to breathe more easily through the nose. The effect of Xylometazoline Decongestant Nasal Spray begins within a few minutes and lasts for up to 10 hours. Xylometazoline Decongestant Nasal Spray 0.1% w/v is generally well tolerated and does not impair the function of ciliated epithelium.

In a double-blind, saline solution controlled study in patients with common cold, the decongestant effect of xylometazoline was significantly superior ($p < 0.0001$) to saline solution based on rhinomanometry measurement at 1 hour after administration of the study drugs.

5.2 Pharmacokinetic properties

Systemic absorption may occur following nasal application of xylometazoline hydrochloride solutions. It is not used systemically.

5.3 Preclinical safety data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride

Disodium edetate dihydrate

Sodium dihydrogen phosphate dihydrate

Disodium hydrogen phosphate dodecahydrate

Sodium chloride

Purified water

6.2 Incompatibilities

No major incompatibilities are known.

6.3 Shelf life

Three years.

6.4 Special precautions for storage

Do not store above 25°C.

Do not freeze

6.5 Nature and contents of container

Amber coloured, transparent glass bottle with a dosage mechanism of polyethylene or polypropylene, and polypropylene cap, content 10 ml.

Pack size: 1 x 10 ml bottle

6.6 Special precautions for disposal and handling

No special requirements

Any unused product or waste material should be disposed of in accordance with local requirements

7 MARKETING AUTHORISATION HOLDER

Manx Healthcare Ltd
Unit 2
Bosworth Avenue
Tournament Fields
Warwick
CV34 6UQ
UK

8 MARKETING AUTHORISATION NUMBER(S)

PL 14251/0086

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

19 November 2003/19 August 2010

10 DATE OF REVISION OF THE TEXT

11/03/2025